Nouvelles AMMs : ipilimumab-nivolumab en association à la chimiothérapie en première ligne dans le cancer bronchique non à petites cellules métastatiques
- 20 February 2021
- journal article
- letter
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (3) , 231-233
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.Journal of Clinical Oncology, 2020
- Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.Journal of Clinical Oncology, 2020
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2019
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2019
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialThe Lancet Respiratory Medicine, 2019
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018